🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise globally, with estimates suggesting more than 82 million new cases each year. Particularly high rates are seen in the African continent and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, the spread of superbugs and the very limited available drugs presently on offer.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Gain Authorization

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists hope that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This milestone signifies a major breakthrough in the management of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Outcomes and Global Access

As per findings detailed in a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This places it at an comparable level with the current standard treatment, which combines two antibiotics. The research included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Doctors directly involved have shared optimism. Having a single-dose, oral treatment like this is hailed as a "game-changer" for managing the epidemic. This is considered crucial to alleviate the strain of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.